EIGR
Eiger BioPharmaceuticals, Inc.
EIGR
EIGR
Delisted
EIGR was delisted on the 10th of April, 2024.
94 hedge funds and large institutions have $252M invested in Eiger BioPharmaceuticals, Inc. in 2022 Q1 according to their latest regulatory filings, with 20 funds opening new positions, 28 increasing their positions, 29 reducing their positions, and 11 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more capital invested
Capital invested by funds: $ → $
more funds holding in top 10
Funds holding in top 10: →
more first-time investments, than exits
New positions opened: | Existing positions closed:
11% more funds holding
Funds holding: 85 → 94 (+9)
3% less repeat investments, than reductions
Existing positions increased: 28 | Existing positions reduced: 29
Holders
94
Holding in Top 10
6
Calls
$2.98M
Puts
$577K
Top Buyers
| 1 | +$14.1M | |
| 2 | +$12.2M | |
| 3 | +$8.32M | |
| 4 |
SCM
Soleus Capital Management
Greenwich,
Connecticut
|
+$6.5M |
| 5 |
Barclays
London,
United Kingdom
|
+$3.87M |
Top Sellers
| 1 | -$1.69M | |
| 2 | -$1.66M | |
| 3 | -$960K | |
| 4 |
Goldman Sachs
New York
|
-$951K |
| 5 |
PA
Perceptive Advisors
New York
|
-$726K |